Drug Trial Radar · NCT04644068
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
702
Actual
Start
Nov 12, 2020
Primary completion
May 28, 2027
Study completion May 28, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Conditions
- Ovarian Cancer
- Breast Cancer
- Pancreatic Cancer
- Prostate Cancer
- Additional Indications Below for Module 4 and 5
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Bladder Cancer
- Gastric Cancer
- Biliary Cancer
- Cervical Cancer
- Endometrial Cancer
- Small Cell Lung Cancer Only in Module 5
Interventions
AZD5305Drug
Oral PARP inhibitor
PaclitaxelDrug
IV Anti-microtubule agent
CarboplatinDrug
IV Platinum chemotherapeutic
T- DxdDrug
IV Antibody-drug conjugate
Dato-DXdDrug
IV Antibody-drug conjugate
CamizestrantDrug
Oral SERD Molecule
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with adverse events/serious adverse eventsTime frame: From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
- The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: From first dose of study treatment until the end of Cycle 1.
Locations
68 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
New York, New York
Research Site
Oklahoma City, Oklahoma
Research Site
Houston, Texas
Research Site
Heidelberg, Australia
Research Site
Melbourne, Australia
Research Site
Vancouver, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Harbin, China
Research Site
Jining, China
Research Site
Shandong, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Taiyuan, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Brno, Czechia
Research Site
Prague, Czechia
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Modena, Italy
Research Site
Naples, Italy
Research Site
Padova, Italy
Research Site
Roma, Italy
Research Site
Chūōku, Japan
Research Site
Kōtoku, Japan
Research Site
Bydgoszcz, Poland
Research Site
Gdansk, Poland
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.